MPR

MagnetisMM-32: Elranatamab Improves PFS in Pretreated Multiple Myeloma

Interim data from the open-label phase 3 MagnetisMM-32 study demonstrate a significant progression free survival benefit with elranatamab monotherapy vs active standard regimens in patients previously ...
MPR

Tradipitant Cuts GLP-1–Induced Vomiting in Phase 3 Trial

Topline phase 3 data show tradipitant significantly reduced semaglutide-associated vomiting and severe nausea in adults with ...
MPR

Florida Dengue Cases Nearly Double A Month After Emergency Declared

HealthDay News — Dengue cases in Florida keep climbing about a month after 3 counties declared states of emergency over the ...
MPR

IDSA: Over Half of Young Child Hep B Cases Trace to Household Contact

HealthDay News — More than half of children younger than 5 years exposed to hepatitis B virus (HBV) are exposed by someone in their household other than their birth mother, according to a study ...
MPR

Treating Depression in Pregnancy Influences Infant Brain Development

HealthDay News — Treating depression with interpersonal psychotherapy during pregnancy influences infant brain development ...
MPR

Patient-Reported Outcomes Worse for Patients With RA Discontinuing TNF Inhibitor

All PROs significantly higher for those discontinuing TNFi at week 12 vs week 0, but not at later time points.
MPR

Once-Daily Oral Icotronkinra Outperforms Placebo in Ulcerative Colitis

Compared with the placebo group, the 400mg group had significantly higher percentages of participants with clinical remission at week 12. HealthDay News — For patients with moderately to severely ...
MPR

DOACs Beneficial for Patients With A-Fib and Prior Intracranial Bleeding

HealthDay News — For patients with atrial fibrillation (AF) and prior intracranial bleeding, direct oral anticoagulants (DOACs) are associated with a reduced risk for ischemic stroke (IS) and death, ...